Periprosthetic joint infection (PJI) is one of the most devastating and costly complications following total joint arthroplasty (TJA). Given the increase of TJA being performed annually, the number of complications necessitating revision surgery is increasing.
PJI, one of the major complications and etiologies of implant failure after TJA, is associated with a substantial financial burden on the healthcare system and significant physical and psychological morbidity on patients. Diagnosis and management of PJI are challenging for surgeons.
Still in ‘stealth mode’, CognitOss Gel is being developed using Locate Bio’s core competency of Programmed Drug Release to bring a powerful new tool to the treatment of PJI.
*For investigational use only, not approved for sale